Last reviewed · How we verify
Tafasitamab plus lenalidomide
Tafasitamab plus lenalidomide is a Small molecule drug developed by MorphoSys AG. It is currently in Phase 1 development.
At a glance
| Generic name | Tafasitamab plus lenalidomide |
|---|---|
| Sponsor | MorphoSys AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (PHASE2)
- A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (PHASE2)
- Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (PHASE1, PHASE2)
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (PHASE3)
- To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (PHASE1, PHASE2)
- Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL (PHASE2)
- Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) (PHASE3)
- Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafasitamab plus lenalidomide CI brief — competitive landscape report
- Tafasitamab plus lenalidomide updates RSS · CI watch RSS
- MorphoSys AG portfolio CI
Frequently asked questions about Tafasitamab plus lenalidomide
What is Tafasitamab plus lenalidomide?
Tafasitamab plus lenalidomide is a Small molecule drug developed by MorphoSys AG.
Who makes Tafasitamab plus lenalidomide?
Tafasitamab plus lenalidomide is developed by MorphoSys AG (see full MorphoSys AG pipeline at /company/morphosys-ag).
What development phase is Tafasitamab plus lenalidomide in?
Tafasitamab plus lenalidomide is in Phase 1.
Related
- Manufacturer: MorphoSys AG — full pipeline
- Compare: Tafasitamab plus lenalidomide vs similar drugs
- Pricing: Tafasitamab plus lenalidomide cost, discount & access